5 completed. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
Follow Recurrent Childhood Central Nervous System Neoplasm: new trials by email Literature Review of Recurrent Childhood Central Nervous System Neoplasm trials Research Report on Recurrent Childhood Central Nervous System Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Vemurafenib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2017-11-08 | 2025-01-27 |
| Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Selumetinib, Selumetinib Sulfate - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2017-10-30 | 2025-02-05 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas Pharmacological Study, Selinexor - Malignant Glioma, Recurrent Brain Neoplasm | Phase 1 | Completed | Children's Oncology Group | 59 | 2015-10-30 | 2025-01-14 |
| Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - Adult Solid Neoplasm, Childhood Solid Neoplasm | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2014-05-16 | 2021-03-26 |
Central Nervous System Neoplasms (5) · Glioma (3) · Lymphoma, Non-Hodgkin (3) · Neuroblastoma (3) · Neuroectodermal Tumors, Primitive, Peripheral (3) · Ependymoma (2) · Hepatoblastoma (2) · Histiocytosis, Langerhans-Cell (2) · Osteosarcoma (2) · Rhabdoid Tumor (2) · Rhabdomyosarcoma (2) · Sarcoma (2) · Wilms Tumor (2) · Astrocytoma (1) · Brain Neoplasms (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Glandular and Epithelial (5) · Neoplasms, Nerve Tissue (5) · Neoplasms, Neuroepithelial (5) · Nervous System Diseases (5) · Nervous System Neoplasms (5) · Neuroectodermal Tumors (5) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4)
AZD 6244 (1) · Temozolomide (1) · Vemurafenib (1) · olaparib (1) · selinexor (1) · talazoparib (1)
National Cancer Institute (NCI) (4) · Children's Oncology Group (1)
United States (5) · Puerto Rico (3)
Julia Glade-Bender (2) · AeRang Kim (1) · Carl E Allen (1) · Eric S Schafer (1)
PMID 31401903, PMID 31724813, PMID 35363510, PMID 38815151, PMID 38873934, PMID 39998852
U10CA180886 (3), UM1CA097452 (2)